COMBIVAS

COMBIVAS is funded by a grant from the MRC to CI Rachel Jones and team. It is sponsored by Cambridge University Hospitals NHS Foundation Trust.

It is a proof of concept mechanistic RCT to assess whether dual B-cell immunotherapy by co-administration of rituximab and belimumab will result in improvements in biological endpoints, functional outcomes and clinical status compared to rituximab with placebo.

You can find out more here, or from COMBIVAS’s registration on ClinicalTrials.gov.